Vaccine, Recombinant] for use in males aged nine to 26 years. It is indicated to prevent certain human papillomavirus (HPV)-related cancers and conditions and marks the first approval of an HPV ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Treatment with Vvax001 -- comprised of replication-deficient recombinant Semliki ... oncogenes in the development of HPV-associated tumors, and therapeutic vaccines targeting HPV16 E6 and E7 ...

A therapeutic vaccine targeting human papillomavirus type ... "Nearly all premalignant cervical lesions and cervical cancers are caused by HPV infection, with HPV16 implicated in the majority ...

A spokeswoman for Mr. Kennedy declined to comment. The first of many lawsuits claiming that young people were harmed by the HPV vaccine is on trial in Los Angeles Superior Court. Mr. Kennedy has ...

The commercial approval in June 2006 of the first HPV vaccine, Gardasil (recombinant HPV subtypes 6/11/16/18), marketed by Whitehouse Station, New Jersey–based Merck, has enabled Ian Frazer to ...

Although we currently have no data regarding the immune response of infants and young children to prophylactic HPV vaccines, there is no reason to believe that it would be very different from ...

The specifications of vaccines are determined by the particular product and its method of manufacture, which raise issues unique to the vaccine in question. However, the general principles are ...

On Facebook, moms debate if the vaccine could harm their kids' reproductive health. And in tweets, people share claims about adverse reactions to the shot. They're all talking about HPV ...